TRUE Test 24 Plaster do prób prowokacyjnych Polska - polski - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

true test 24 plaster do prób prowokacyjnych

smartpractice demnark aps - niccoli sulphas + alkohole sterolowe z lanoliny + neomycyny siarczan + kalii dichromas + mieszanina kain + mieszanina substancji zapachowych + kalafonia + paraben mix + quinoline mix + balsamum peruvianum + ethylenediamini dihydrochloridum + kobaltu chlorek + p-tert butylphenol formaldehyde resin + epoxy resin + carba mix + black rubber mix + methyl chloro isothiazolinone (kathon cg) + quaternium-15 + mercaptobenzothiazole + p-phenylenediaminum + formaldehydum + mercapto mix + tiomersal + thiuram mix - plaster do prób prowokacyjnych

TRUE Test 36 - Plaster do prób prowokacyjnych Polska - polski - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

true test 36 - plaster do prób prowokacyjnych

smartpractice demnark aps - niccoli sulphas + alkohole sterolowe z lanoliny + kalii dichromas + mieszanina kain + mieszanina substancji zapachowych + kalafonia + paraben mix + balsamum peruvianum + ethylenediamini dihydrochloridum + kobaltu chlorek + p-tert butylphenol formaldehyde resin + epoxy resin + carba mix + black rubber mix + metylochloroizotiazolinon + quaternium-15 + mercaptobenzothiazole + p-phenylenediaminum + formaldehydum + mercapto mix + tiomersal + thiuram mix + diazolidynylomocznik + quinoline mix + imidazolidynylomocznik + budesonidum + hydrocortisoni butyras + mercaptobenzothiazole + bacytracyna + bronopol (2-bromo-2-nitro-propan-1,3-diol) + propylis parahydroxybenzoas + kobaltu (ii) chlorek + eugenolum + cynchokainy chlorowodorek + metylu parahydroksybenzoesan + alkohol cynamonowy + benzyli benzoas + geranii aetheroleum + butylu parahydroksybenzoesan + benzocainum + tetracaini hydrochloridum + etylu parahydroksybenzoesan + hydroksycytronellal + aldehyd cynamonowy - plaster do prób prowokacyjnych - -

Abiraterone Accord Unia Europejska - polski - EMA (European Medicines Agency)

abiraterone accord

accord healthcare s.l.u. - octan abirateronu - nowotwory stercza - terapia endokrynologiczna - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Abiraterone Mylan Unia Europejska - polski - EMA (European Medicines Agency)

abiraterone mylan

mylan ireland limited - octan abirateronu - nowotwory stercza - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Abiraterone Krka Unia Europejska - polski - EMA (European Medicines Agency)

abiraterone krka

krka, d.d., novo mesto - octan abirateronu - nowotwory stercza - terapia endokrynologiczna - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.